Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
WELCOME TO THE SOUND OF SCIENCE PODCAST PAGE!
This series covers several topics regarding the progress made in the treatment landscape of HIV over the last couple of years, best practices in HIV care, as well as the importance of healthcare professional - people living with HIV (PLHIV) dialogue and shared decision-making.
Episode 1 SOLAR Data – What does this mean for people living with HIV (PLHIV)?
This episode highlights the key data and conclusions that can be drawn from the SOLAR results that were presented during the 30th Conference on Retroviruses and Opportunistic Infections (CROI), held in Seattle, Washington.
SPEAKERS
PROF. CHLOE ORKIN, LEAD FOR HIV RESEARCH AT BARTS HEALTH NHS TRUST, LONDON, UK AND DR PERRY MOHAMMED, HEAD OF MEDICAL AFFAIRS, EUROPE, ViiV HEALTHCARE.
PM-IE-CBR-AUDI-240001 | April 2024
Vocabria▼+ Rekambys▼ Prescribing Information
▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
-
References and Adverse Event Reporting - Ramgopal MN, et al. Lancet HIV 2023;10:e566–e577;ePub ahead of print (and suppl. appendix)
- Chounta V, et al. IAS 2023. Poster TUPEB06
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.
REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.
All other trademarks are owned by the ViiV Healthcare group, or its licensor.
©2024 GSK group of companies. All rights reserved.
Date of preparation: April 2024 | PM-IE-HVX-WCNT-240002
